Hemophagocytic Lymphohistiocytosis (HLH)

Definition and Core Pathophysiology

HLH is a life-threatening hyperinflammatory syndrome caused by uncontrolled activation of CD8+ T lymphocytes, NK cells, and macrophages/histiocytes, leading to a cytokine storm and multi-organ damage (Robbins & Kumar Basic Pathology, p. 401; Harrison's Principles of Internal Medicine 22E).

The central mechanism: inherited or acquired defects impair the cytolytic (killing) function of cytotoxic T cells and NK cells. Because these "killer lymphocytes" cannot efficiently destroy their targets (e.g., virus-infected cells), they remain engaged with target cells for abnormally long periods, driving excessive release of IFN-γ. This overdrives macrophage activation, producing toxic levels of proinflammatory cytokines (TNF, IL-6, IL-18, soluble IL-2 receptor/CD25) - a picture that clinically mimics sepsis or systemic inflammatory response syndrome (Robbins Basic Pathology, p. 401). Activated macrophages then phagocytose red cells, platelets, and nucleated marrow precursors ("hemophagocytosis"), which is why the syndrome is also called macrophage activation syndrome (MAS) when triggered by autoimmune disease.

Classification

HLH is divided into primary (genetic) and secondary (acquired) forms, though the clinical phenotype converges (Harrison's, Ch. 68, Jan-Inge Henter):

Primary HLH - Mendelian conditions

Familial HLH (FHL) subtypes from lymphocyte cytotoxic defects:
- FHL2 - PRF1 (perforin deficiency, ~30% of familial cases)
- FHL3 - UNC13D (Munc13-4 deficiency, ~30%)
- FHL4 - STX11 (syntaxin-11 deficiency, ~10%)
- FHL5 - STXBP2 (Munc18-2 deficiency, ~20%)
- Rare: FAAP24, RHOG mutations
HLH with partial albinism (pigmentary disorders with cytotoxic defects): Chédiak-Higashi syndrome (giant lysosomal granules, progressive neurologic disease), Griscelli syndrome type 2, Hermansky-Pudlak syndrome type II
X-linked lymphoproliferative disease (XLP1, SH2D1A/SAP deficiency) and XLP2 (BIRC4/XIAP deficiency) - both classically triggered by EBV infection
Inflammasome/other Mendelian disorders: NLRC4 gain-of-function, lysinuric protein intolerance, Wolman disease

Secondary (non-Mendelian) HLH

Infection-associated: viral (EBV is the classic and most common trigger), bacterial, parasitic, fungal
Malignancy-associated (especially peripheral T-cell/NK-cell lymphomas, or occurring during chemotherapy)
Autoimmune-associated (MAS-HLH): systemic juvenile idiopathic arthritis, adult-onset Still's disease, SLE, vasculitis
Transplant-associated HLH

Primary HLH predominantly affects infants and children (often presenting in the first year of life, occasionally at birth); secondary HLH is far more common in adults.

Clinical Features

Fever, hepatosplenomegaly, lymphadenopathy, edema
Cytopenias (affecting ≥2 of: hemoglobin, platelets, neutrophils)
Neurologic manifestations (irritability, seizures, altered consciousness - CNS involvement is common and prognostically important)
Coagulopathy, sometimes progressing to DIC
Elevated liver enzymes, hepatic dysfunction
In severe cases: multi-organ failure and death if untreated

Key Laboratory/Diagnostic Findings

Markedly elevated ferritin (classically >10,000 μg/L is highly suggestive, though lower levels don't exclude it)
Hypertriglyceridemia
Hypofibrinogenemia
Elevated soluble IL-2 receptor (sCD25) - a marker of T-cell activation
Low or absent NK cell cytotoxicity; reduced circulating NK cells and CD8+ T cells
Hemophagocytosis on bone marrow or CSF examination (macrophages engulfing RBCs, platelets, and nucleated marrow cells) - supportive but neither required nor sufficient alone for diagnosis
Functional assays (e.g., CD107a degranulation assay) and genetic testing help identify genetically determined HLH, along with assessment of intracellular perforin expression

Diagnosis is clinical, built on this constellation of features (fever, hepatosplenomegaly, cytopenias, hypofibrinogenemia/hypertriglyceridemia, hyperferritinemia, elevated T-cell activation markers, hemophagocytic features) rather than any single test.

Treatment

Immunosuppression/chemotherapy: Etoposide-based regimens (e.g., HLH-94/HLH-2004 protocols combining etoposide, dexamethasone, +/- cyclosporine) remain a backbone of therapy, particularly in genetic HLH and severe presentations (Harrison's, Ch. 68/362).
Targeted biologics: anti-T-cell antibodies; agents targeting the IFN-γ pathway (e.g., emapalumab, an anti-IFN-γ monoclonal antibody) and JAK1/2 inhibition, which interrupt the cytokine-driven amplification loop.
Hematopoietic stem cell transplantation (HSCT): offers the only chance of cure for patients with inherited (genetic) HLH, since the underlying cytotoxic lymphocyte defect persists otherwise.
Treat the trigger: for secondary HLH, addressing the underlying infection, malignancy, or autoimmune disease is essential alongside immunosuppression.
Treatment is tailored to etiology, but outcomes are often poor even with treatment, especially in delayed diagnosis or CNS involvement.

Recent Evidence (surfacing per protocol - may refine/update the above)

A few recent systematic reviews/meta-analyses are worth flagging since they touch directly on treatment choices discussed above:

A 2025 systematic review/meta-analysis (PMID: 39955467) specifically assessed etoposide effectiveness in adult HLH - useful since much of the etoposide evidence base (HLH-94/2004) was pediatric-derived; adult outcomes and optimal dosing may differ.
A 2024 systematic review (PMID: 38934172) evaluated rituximab as a therapeutic strategy in HLH, particularly EBV-driven HLH, an option not covered in the textbook excerpts above (targets EBV-infected B cells rather than the cytokine storm directly).
A 2023 meta-analysis (PMID: 36579732) looked at treatment and mortality in critically ill children with HLH, relevant for ICU-level decision-making.

These don't contradict the textbook framework but add more granular, population-specific outcome data (adults, EBV-driven disease, pediatric ICU) that a clinician managing a real case should review directly if treatment decisions are being made.

This is a shared conversation. Sign in to Orris to start your own chat.